

# Resolution passed at annual general meeting

ASX Announcement 12<sup>th</sup> November 2012  
Tissue Therapies Limited ABN 45 101 955 088

## Announcement

At the Annual General Meeting of Biomedical company, Tissue Therapies Limited (ASX: TIS) held on 12 November 2012, the following resolutions were passed on a show of hands:

### 1. Directors' Remuneration Report

'That the Remuneration Report be adopted.'

### 2. Re-election of Mel Bridges

'That Mel Bridges, who retires in accordance with Rule 16.1 of the Company's Constitution, and being eligible, and having offered himself for re-election, be re-elected as a Director of the Company.'

### 3. Re-election of Cherrell Hirst

'That Cherrell Hirst, who retires in accordance with Rule 16.1 of the Company's Constitution, and being eligible, and having offered herself for re-election, be re-elected as a Director of the Company.'

### 4. Re-election of Iain Ross

'That Iain Ross, who was appointed to fill a casual vacancy and retires in accordance with Listing Rule 14.4 and Rule 13.2 of the Company's Constitution, and being eligible, be re-elected as a Director of the Company.'

### 5. Ratification and Approval of Previous Allotment and Issue of Shares under a Placement

'That for the purposes of Listing Rule 7.4 and for all other purposes, approval be given for the previous issue of 3,000,000 shares at an issue price of \$0.37 per share, issued under a placement to a sophisticated investor as detailed in the Explanatory Memorandum which accompanied the Notice of Meeting.'

### 6. Ratification and Approval of Previous Allotment and Issue of Shares for Consultancy Services

'That for the purposes of Listing Rule 7.4 and for all other purposes, approval be given for the previous issue of 115,712 ordinary shares at an issue price of \$0.52 per share and 127,160 ordinary shares at an issue price of \$0.41 per share to Mr Geoff Morris in part payment of consultancy services provided to Tissue Therapies pursuant to a Consultancy Agreement, the terms of which are summarised in the Explanatory Memorandum which accompanied the Notice of Meeting.'

### 7. Ratification and Approval of Previous Allotment and Issue of Shares for Consultancy Services

'That for the purposes of Listing Rule 7.4 and for all other purposes, approval be given for the previous issue of 14,898 ordinary shares at an issue price of \$0.49 per share to Ms Patsy Trisler in part payment of consultancy services provided to Tissue Therapies pursuant to a Consultancy Agreement, the terms of which are summarised in the Explanatory Memorandum which accompanied the Notice of Meeting.'

### 8. Ratification and Approval of Previous Allotment and Issue of Shares Following the Exercise of Options Issued Under the Existing Equity Option Plan

'That for the purposes of Listing Rule 7.4 and for all other purposes, approval be given for the previous issue of 360,000 ordinary shares at an issue price of \$0.26 per share and 25,000 ordinary shares at an issue price of \$0.15 per share to employees of Tissue Therapies Limited and Queensland University of Technology (QUT) who exercised options issued under the existing Equity Option Plan the terms of

# Resolution passed at annual general meeting

ASX Announcement 12<sup>th</sup> November 2012  
Tissue Therapies Limited ABN 45 101 955 088

which are summarised in the Explanatory Memorandum which accompanied the Notice of Meeting.'

## 9. Approval of New Equity Option Plan

'That, for the purpose of Listing Rule 7.2, exception 9(b) and for all other purposes, the Company approve the issue of securities under the Equity Option Plan of the Company, the terms and conditions of which are summarised in the Explanatory Memorandum which accompanied the Notice of Meeting.'

## 10. Approval of additional capacity to issue shares under Listing Rule 7.1A

'For the purposes of ASX Listing Rule 7.1A and for all other purposes, shareholders approve the Company having the additional capacity to issue equity securities under Listing Rule 7.1A, on the terms and conditions set out in the Explanatory Memorandum.'

## Summary of Proxy Votes Lodged

Resolution Name	For	At Discretion of Proxy Holder	Against	Abstain
1	41,632,117	831,858	1,480,537	140,740
2	49,127,155	2,986,221	866,736	118,682
3	49,252,133	3,012,650	765,329	68,682
4	49,248,133	3,012,650	769,329	68,682
5	48,674,456	3,018,650	1,239,844	165,844
6	48,518,593	3,056,937	1,325,098	198,166
7	48,545,218	3,056,937	1,329,696	166,943
8	41,141,199	3,017,175	1,828,150	286,520
9	40,779,745	822,858	1,952,959	524,036
10	48,320,431	3,013,175	1,480,178	285,010

# Resolution passed at annual general meeting

ASX Announcement 12<sup>th</sup> November 2012  
Tissue Therapies Limited ABN 45 101 955 088

## What is VitroGro<sup>®</sup> ECM

- VitroGro<sup>®</sup> ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- **How it works:** VitroGro<sup>®</sup> ECM replaces the degraded matrix of a hard to heal wound. VitroGro<sup>®</sup> ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration <sup>[1]</sup>.
- **An optimal scaffold:** One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process <sup>[1,2,3,4]</sup>. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds <sup>[1]</sup>. VitroGro<sup>®</sup> ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro<sup>®</sup> ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

## About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro<sup>®</sup> ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)



Tissue Therapies Limited  
ABN 45 101 955 088  
Level 19, 179 Turbot Street, Brisbane, QLD 4000 Australia  
[www.tissuetherapies.com](http://www.tissuetherapies.com)